ProCE Banner Activity


Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals


Learn how to recommend therapies for myelofibrosis reflecting a best-practice strategy based on current data and expert recommendations and taking into account patients’ risk of relapse and disease features. Continue watching to learn how to formulate adverse event management plans collaboratively with patients to ensure optimal quality of life and persistence on treatment.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: May 16, 2024

Expiration: May 15, 2025



Justin R. Arnall

Justin R. Arnall, PharmD, BCOP

Clinical Coordinator, Hematology
Atrium Health Specialty Pharmacy Service
Charlotte, North Carolina

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC In partnership with Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from GlaxoSmithKline.



Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with myelofibrosis, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Program Learning Goal

The goal of this educational program is to improve managed care pharmacy professionals’ knowledge and competence related to recognizing the clinical implications associated with suboptimal treatment of MF and understanding the unmet needs in care, making evidence-based recommendations based on the latest clinical data surrounding novel and emerging therapies, and developing strategies to support patient-centered care in MF.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend available therapies reflecting a best-practice strategy for first-line treatment of patients with MF based on available data and expert recommendations, considering risk of relapse, molecular features, cytogenetics, and symptom burden

  • Develop evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy

  • Assess the toxicity profiles of current and emerging MF therapies to collaboratively formulate an adverse event management plan that supports quality of life and continuation of treatment

  • Explain new data on emerging agents for MF to educate colleagues and counsel eligible patients regarding ongoing trial opportunities


ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Justin R. Arnall, PharmD, BCOP

Clinical Coordinator, Hematology
Atrium Health Specialty Pharmacy Service
Charlotte, North Carolina

Justin R. Arnall, PharmD, BCOP, has no relevant financial relationships to disclose.

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 16, 2024, through May 15, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-008-H01-P  has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hour (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.